<!-- LLM_VERSION_INFO
FORMAT: text/markdown
CONTENT_TYPE: article
ORIGINAL_URL: https://enablemedicine.com/research/multiplex-imaging-and-analysis-using-the-enable-cloud-platform-to-predict-tnf-inhibitor-response-in-ulcerative-colitis-patients
ALTERNATE_VERSION: research/multiplex-imaging-and-analysis-using-the-enable-cloud-platform-to-predict-tnf-inhibitor-response-in-ulcerative-colitis-patients.html (text/html)
EXTRACTION_DATE: 2026-04-18T23:18:10.013Z

This is the markdown version with text-only content (images converted to alt-text).
For rich formatting with images, request the HTML version at: research/multiplex-imaging-and-analysis-using-the-enable-cloud-platform-to-predict-tnf-inhibitor-response-in-ulcerative-colitis-patients.html
-->

# Multiplex imaging and analysis using the Enable Cloud Platform to predict TNF inhibitor response in ulcerative colitis patients

## Case study

April 1, 2023

Ulcerative colitis (UC) is a chronic-relapsing inflammatory bowel disease (IBD). Patients with UC have a 1.5 times higher risk for colorectal cancer compared to healthy individuals. TNF inhibitors such as infliximab and adalimumab are frontline targeted therapies for UC but 13-40% UC patients are non-responsive to TNFi therapy and up to 46% show loss of resistance. Since these drugs are immunosuppressive, they can lead to opportunistic infections, driving up the cost following UC treatment, especially in non-responders. In order to implement individualized therapy to patients effectively, it is critical to understand the differences between individual patients that could affect responses to TNF therapy.

.svg)

## Download Resource

[Download the PDF](https://cdn.prod.website-files.com/65ca6abb275ffa2a6cd94f2e/6601d84e3ca83f8f33f6e62c_Enable%20Medicine%20Ulcerative%20Colitis%20Tech%20Note%20(2)-min.pdf)